86 related articles for article (PubMed ID: 19036078)
1. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial.
Hancock BW; Qian W; Linch D; Delchier JC; Smith P; Jakupovic I; Burton C; Souhami R; Wotherspoon A; Copie-Bergman C; Capella C; Traulle C; Levy M; Cortelazzo S; Ferreri AJ; Ambrosetti A; Pinotti G; Martinelli G; Vitolo U; Cavalli F; Gisselbrecht C; Zucca E
Br J Haematol; 2009 Feb; 144(3):367-75. PubMed ID: 19036078
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori-negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: A clinicopathologic analysis.
Gu SX; Siddon AJ; Huntington SF; Jain D
Am J Clin Pathol; 2023 Dec; 160(6):612-619. PubMed ID: 37556379
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials.
Zinzani PL; Viviani S; Anastasia A; Vitolo U; Luminari S; Zaja F; Corradini P; Spina M; Brusamolino E; Gianni AM; Santoro A; Botto B; Derenzini E; Pellegrini C; Argnani L
Haematologica; 2013 Aug; 98(8):1232-6. PubMed ID: 23645687
[TBL] [Abstract][Full Text] [Related]
4. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature.
Kiesewetter B; Raderer M
Blood; 2013 Aug; 122(8):1350-7. PubMed ID: 23770778
[TBL] [Abstract][Full Text] [Related]
7. MALT lymphomas: pathogenesis can drive treatment.
Bertoni F; Coiffier B; Salles G; Stathis A; Traverse-Glehen A; Thieblemont C; Zucca E
Oncology (Williston Park); 2011 Nov; 25(12):1134-42, 1147. PubMed ID: 22229204
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
Kang HJ; Kim WS; Kim SJ; Lee JJ; Yang DH; Kim JS; Lee SR; Lee GW; Kim HJ; Kim HY; Oh SY; Kim HC; Eom HS; Chung J; Park J; Suh C; Ryoo BY
Ann Hematol; 2012 Apr; 91(4):543-51. PubMed ID: 21922208
[TBL] [Abstract][Full Text] [Related]
9. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT.
Ruskoné-Fourmestraux A; Fischbach W; Aleman BM; Boot H; Du MQ; Megraud F; Montalban C; Raderer M; Savio A; Wotherspoon A;
Gut; 2011 Jun; 60(6):747-58. PubMed ID: 21317175
[TBL] [Abstract][Full Text] [Related]
10. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.
Blood; 1997 Jun; 89(11):3909-18. PubMed ID: 9166827
[TBL] [Abstract][Full Text] [Related]
11. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.
Wotherspoon AC; Doglioni C; Diss TC; Pan L; Moschini A; de Boni M; Isaacson PG
Lancet; 1993 Sep; 342(8871):575-7. PubMed ID: 8102719
[TBL] [Abstract][Full Text] [Related]
12. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
13. Physiologic colonic uptake of
Cvetkovic L; Régis C; Richard C; Derosa L; Leblond A; Malo J; Messaoudene M; Desilets A; Belkaid W; Elkrief A; Routy B; Juneau D
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1550-1559. PubMed ID: 33128571
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal.
Raderer M; Kiesewetter B; Du MQ
Ther Adv Med Oncol; 2023; 15():17588359231183565. PubMed ID: 37389189
[TBL] [Abstract][Full Text] [Related]
15. Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives.
Kaddu-Mulindwa D; Thurner L; Christofyllakis K; Bewarder M; Kos IA
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740684
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following
Raderer M; Kiesewetter B; Mayerhoefer ME
Expert Rev Hematol; 2022 Jul; 15(7):565-571. PubMed ID: 35695746
[TBL] [Abstract][Full Text] [Related]
17. What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments.
Raderer M; Kiesewetter B
Ther Adv Med Oncol; 2021; 13():17588359211033825. PubMed ID: 34621332
[TBL] [Abstract][Full Text] [Related]
18. Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma.
Scheibenpflug R; Obermüller M; Reznicek G; Neuper O; Lamm WW; Raderer M; Lagler H
Sci Rep; 2021 Sep; 11(1):18460. PubMed ID: 34531427
[TBL] [Abstract][Full Text] [Related]
19. Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.
Kiesewetter B; Simonitsch-Klupp I; Dolak W; Mayerhoefer ME; Raderer M
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093228
[TBL] [Abstract][Full Text] [Related]
20. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
